HTL Biotechnology inaugurates a new production line dedicated to sterile Hyaluronic Acid
As part of National Biomanufacturing Day 2025, HTL Biotechnology inaugurates a new production line dedicated to Hyaluronic Acid.
Press releases
March 10, 2022
GelMEDIX
This partnership represents the first equity investment of the incubator created by HTL to accelerate the development of innovative treatments using biopolymers in therapeutic areas with unmet medical needs.
HTL will provide financial, industrial and scientific support to GelMEDIX to facilitate the development of next generation ocular and regenerative therapies based on its proprietary hydrogel platform.
This platform enables the delivery of therapeutics from small molecules to cell and gene therapies.
To see our most recent news,
follow us on LinkedIn
Read more
news from us
-
Articles October 9, 2025HTL Biotechnology rallies for Pink October 2025
This October, HTL Biotechnology turned pink to support breast cancer prevention.
-
Articles September 19, 2025HTL Biotechnology wins the Responsible Care 2025 Award
HTL Biotechnology is the winner of the Responsible Care West Atlantic Trophy in the ‘Energy – Climate’ category for its project to reduce carbon emissions from distillation systems.
-
Articles September 13, 2025Looking Back at Our Presence at ESCRS 2025
The European Society of Cataract and Refractive Surgeons (ESCRS) is a unique opportunity each year to connect with our clients and partners while gaining insights into the key trends shaping the future of ophthalmology.